<DOC>
	<DOCNO>NCT02784795</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3039478 combination anticancer agents participant advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study LY3039478 Participants With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>For part : The participant must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit advance metastatic cancer . For dose escalation combination : The participant must histological cytological evidence cancer , either solid tumor lymphoma , advance metastatic . For Part A dose confirmation : All participant must histological evidence advanced metastatic soft tissue sarcoma breast cancer . Breast cancer participant must prescreened mutation , amplification , gene/protein expression alteration relate Notch pathway . For Part B dose confirmation : All participant must histological evidence advanced metastatic colon cancer soft tissue sarcoma . Colon cancer participant must prescreened mutation , amplification , gene/protein expression alteration relate Notch pathway . For Part C dose confirmation : All participant must histological evidence advanced metastatic breast cancer prescreened mutation , amplification , gene/protein expression alteration relate Notch pathway . For Part D dose confirmation : All participant must histological evidence cholangiocarcinoma prescreened mutation , amplification , gene/protein expression alteration relate Notch pathway . Participants must receive &gt; 1 line prior systemic therapy metastatic resectable disease ( , participant may receive adjuvant gemcitabine later gemcitabine/cisplatin recurrent metastatic disease ) . For Part E dose confirmation : All participant must histological evidence locally advance metastatic triple negative breast cancer ( TNBC ) prescreened mutation , amplification , gene/protein expression alteration relate Notch pathway . Participants must receive &gt; 2 line systemic treatment advance metastatic TNBC . Have adequate organ function . Have performance status â‰¤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous therapy cancer . Have current acute leukemia . Have current recent ( within 3 month study drug administration ) gastrointestinal disease chronic intermittent diarrhea , disorder increase risk diarrhea , inflammatory bowel disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Notch Inhibitor</keyword>
</DOC>